EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report

Hironori Yamaguchi, Hideyuki Ohzawa, Hideyo Miyato, Kenichi Ohshiro, Kensuke Yokoyama

Case Reports in Oncology · 11.09.2026 · 19 (1) · 1704-1712

DOI: 10.1159/cro/abzag056 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 11.09.2026. Verfasst von Hironori Yamaguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal, General and Transplant Surgery, Jichi Medical University, Shimotsuke, Japan. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tropomyosin receptor kinase (TRK) inhibitors have demonstrated remarkable efficacy in patients with NTRK fusion-positive malignancies; however, their long-term effects on skeletal health remain incompletely understood. Case Presentation: We report a 65-year-old woman with an ETV6-NTRK3 fusion-positive gastrointestinal stromal tumor who achieved sustained disease control during prolonged TRK inhibitor therapy. During treatment, she developed progressive skeletal fragility characterized by multiple atraumatic fractures, delayed fracture healing, and progressive lumbar spinal destruction consistent with Charcot-like neuropathic arthropathy. Neurological deterioration, including loss of ambulation, resulted from structural spinal instability rather than direct neurotoxicity. Although initial imaging findings raised suspicion of metastatic disease, serial CT, MRI, and FDG-PET/CT examinations supported a nonmalignant skeletal process in the setting of continued oncologic remission. Following discontinuation of TRK inhibitor therapy, neurological symptoms stabilized and radiographic evidence of fracture healing was observed.

Conclusion

This case suggests that TRK inhibitor-associated skeletal toxicity may represent an on-target effect related to disruption of neuro-skeletal interactions. Long-term monitoring of bone health may be warranted in patients receiving prolonged TRK inhibitor therapy.

Schlagwörter

Stichwörter der Autor:innen

Charcot spinal arthropathyLarotrectinibNTRK fusion-positive cancerSkeletal fragilityTropomyosin receptor kinase inhibitor-associated skeletal toxicity

Autor:innen und Institutionen

  • Department of Gastrointestinal, General and Transplant Surgery, Jichi Medical University, Shimotsuke, Japan.
  • Department of Clinical Oncology, Jichi Medical University Hospital, Shimotsuke, Japan.
  • Department of Gastroenterology, Jichi Medical University, Shimotsuke, Japan.

Zitieren

APA

Yamaguchi, H., Ohzawa, H., Miyato, H., Ohshiro, K., & Yokoyama, K. (2026). Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report. Case Reports in Oncology, 19(1), 1704-1712. https://doi.org/10.1159/cro/abzag056

Vancouver

Yamaguchi H, Ohzawa H, Miyato H, Ohshiro K, Yokoyama K. Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report. Case Reports in Oncology. 2026;19(1):1704-1712. doi:10.1159/cro/abzag056

BibTeX
@article{Yamaguchi2026,
  author = {Yamaguchi, Hironori and Ohzawa, Hideyuki and Miyato, Hideyo and Ohshiro, Kenichi and Yokoyama, Kensuke},
  title = {Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {1704--1712},
  doi = {10.1159/cro/abzag056}
}
Kostenlos starten →